N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 PERIODONTAL DISEASE AND HYPERLIPIDEMIA
Hyperlipidemia, Periodontitis, Gingivitis
Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml
Phase 2 N=59 LIPIDS-P Trial Phase I/II Trial
Sepsis, Severe · Septic Shock
Primary: Phase II - Primary Outcome - Change in Total Cholesterol (48 Hours - Enrollment) — 9; -10; 4; 2 mg/dL
N/A N=27 How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
Non-alcoholic Fatty Liver Disease (NAFLD)
Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05
Phase 2 N=10 Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Familial Partial Lipodystrophy
Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides
Phase 2 N=5 Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Lipodystrophy
Primary: Change in Log 10 Fasting Triglycerides. — 0.1; -0.2 log 10 mg/dl
N/A N=70 Lipid Biomarkers for Diabetic Heart Disease
Type II Diabetes Mellitus · Diabetes Complications
Primary: Change in Cardiac Diastolic Function as Measured by E' (cm/s) — -0.02; 0.55 cm/s — p=0.07
N/A N=106 Lipid Metabolism in Gestational Diabetes
Gestational Diabetes · Hyperlipidemia
Primary: Cholesterol — 204; 201 mg/dl
N/A N=514 Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
Dyslipidemias · Hypercholesterolemia · Hypertriglyceridemia
Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL
Phase 3 N=542 Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
Dyslipidemias · Coronary Heart Disease · Combined (Atherogenic) Dyslipidemia
Primary: Median Percent Change in Triglycerides From Baseline to Final Visit — -57.3; -39.7 Percent change — p=< 0.001
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 3 N=682 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
Coronary Artery Disease · Coronary Heart Disease · Dyslipidemia
Primary: Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT) — -0.006; 0.000 mm/year — p=0.220
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
Phase 2 N=103 Leptin to Treat Lipodystrophy
Lipodystrophy
Primary: Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin — 8.4; 8.1; 6.6; 7.2 percentage of glycated hemoglobin — p=<0.001
N/A N=4 HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
HIV Infections
Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg
Phase 3 N=609 Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Mixed Dyslipidemia · Coronary Heart Disease · Dyslipidemia
Primary: Mean Percent Change in Triglycerides From Baseline to Final Visit — -45.6; -42.1; -29.6; -16.5 percent change — p=<0.001
N/A N=74 Lipids, Inflammation, and CV Risk in RA
Rheumatoid Arthritis · Cardiovascular Disease
Primary: Coronary Flow Reserve — 2.65 ratio
Phase 3 N=128 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Treatment Difference in Coefficient of Fat Absorption (CFA) Change From Baseline — -11.852 percent change from baseline
Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
N/A N=8 Acute Microvascular Changes With LDL Apheresis
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
Phase 2 N=107 A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
Atherosclerosis
Primary: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity — 0.961; 0.494; 0.404; 0.313 Log(millimole per milliliter per minute)…
N/A N=1,271 The Lipid-Rich Plaque Study
Coronary Artery Disease · Atherosclerosis
Primary: Number of Participants Stratified as Non-Index Culprit Lesion Related Major Adverse Cardiac Events (NC-MACE) or No NC-MACE and Association With maxLCBI4mm as a…
Phase 3 N=1,439 Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
Dyslipidemia · Coronary Heart Disease · Mixed Dyslipidemia
Primary: Mean Percent Change in Triglycerides From Baseline to Final Visit — -47.1; -42.9; -32.6; -24.4 percent change — p=<0.001
N/A N=15 Evaluation of Lipid Emulsion on GCX in Critically Ill Patients
Endothelial Dysfunction
Primary: Endothelial Glycocalyx Thickness — 2.28 micrometer
Phase 1 N=18 A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
Dyslipidemias
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B — 0…
Phase 4 N=32 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
Phase 4 N=87 Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy
Coronary Artery Disease
Primary: Lipiscan - Lipid Core Burden Index (LCBI) — 95.4; 132.4; 99.9; 99.8 ratio
N/A N=2,196 Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
Dyslipidemia
Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants
N/A N=687 Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Cardiovascular Diseases · Coronary Artery Disease
Primary: Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit — 51.52 percentage of participants
Phase 4 N=11 Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Generalized Lipodystrophy
Primary: Evaluate the Immunogenicity Associated With Daily Subcutaneous (SC) Metreleptin Treatment in Patients With Congenital Generalized Lipodystrophy (CGL) or Acquired…